Objective:

To create a real-life data infrastructure for evaluating clinical and patient-reported outcomes in prostate cancer treatment and to facilitate various interventional trials, including those focused on new treatment modalities.

Key Findings:

• The UPC study provides a framework for evaluating new prostate cancer treatments in a real-world setting, enhancing the relevance of clinical research.
• Patient-reported outcomes are systematically collected to assess quality of life during and after treatment, providing critical insights into patient experiences.
• The TwiCs design allows for efficient recruitment and evaluation of multiple interventions, potentially accelerating the development of new therapies.

Interpretation:

The UPC serves as a pioneering model for integrating patient-reported outcomes into prostate cancer treatment evaluations, potentially enhancing the relevance and applicability of clinical research by aligning it more closely with patient experiences.

Limitations:

• Exclusion of patients who are mentally incompetent or do not understand Dutch may limit generalizability, particularly in diverse populations.
• Potential biases in patient selection and reporting may affect outcome measures, necessitating careful interpretation of results.

Conclusion:

The UPC study represents a significant advancement in the evaluation of prostate cancer treatments, leveraging a cohort-based approach to enhance patient involvement and outcome assessment, ultimately aiming to improve treatment strategies.